Could a common diabetes drug help adult heart defect patients?

NCT ID NCT06260059

Recruiting now Disease control Sponsor: Anita Saraf Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Empagliflozin (Jardiance), a drug used for diabetes and heart failure, can help adults born with heart defects who now have a weakened heart. Forty participants will receive either the drug or a placebo for one year. Researchers will measure changes in heart function, exercise ability, and hospitalizations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (Jardiance)
What this could lead to: If it works, this could point toward a new treatment option for adults with congenital heart disease who develop heart failure.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The drug may not improve heart function or exercise capacity as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT CONGENITAL HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital heart disease heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT CONGENITAL HEART DISEASE HEART FAILURE

Contacts and locations

Locations

Children's Hospital of Pittsburgh
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States
Magee Women's Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Presbyterian Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.